FBXO11
FBXO11 (F-box only protein 11) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Endometrial cancer, Ovarian cancer and 5 more.
Overview
Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins, such as DTL/CDT2, BCL6, SNAI1 and PRDM1/BLIMP1. The SCF(FBXO11) complex mediates ubiquitination and degradation of BCL6, thereby playing a role in the germinal centre B-cells terminal differentiation toward memory B-cells and plasma cells. The SCF(FBXO11) complex also mediates ubiquitination and degradation of DTL, an important step for the regulation of TGF-beta signalling, cell migration and the timing of the cell-cycle progression and exit.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.83 (direct and indirect evidence; datatypes literature 0.96, animal model 0.49, genetic association 0.87, somatic mutation 0.97). IntOGen calls it a driver in 5 cohorts (1 activating, 4 loss-of-function), covering Burkitt Lymphoma, Malignant Lymphoma, Non-Hodgkin Lymphoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · FBXO11 (F-box only protein 11) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Endometrial cancer, Ovarian cancer and 5 more.
- 1 · What it is
FBXO11 (F-box only protein 11) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Endometrial cancer, Ovarian cancer and 5 more.
- 2 · What goes wrong in cancer
Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins, such as DTL/CDT2, BCL6, SNAI1 and PRDM1/BLIMP1.
- 3 · How drugs use it
No product in this corpus aims at FBXO11 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:13590 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q86XK2 (protein name, function text, keywords and locations (REST API)); CIViC gene FBXO11 (1 evidence items, 0 assertions, 1 variants; diseases: Burkitt Lymphoma (GraphQL API, CC0)); Open Targets ENSG00000138081 (association with cancer (MONDO_0004992) 0.83; per-cancer scores at or above 0.5: colorectal cancer 0.79, gastric cancer 0.65, prostate cancer 0.60, ovarian cancer 0.72, endometrial cancer 0.74, melanoma 0.52 (GraphQL API, CC0)); IntOGen FBXO11 (driver in 5 cohorts (Act 1, LoF 4); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins, such as DTL/CDT2, BCL6, SNAI1 and PRDM1/BLIMP1. The SCF(FBXO11) complex mediates ubiquitination and degradation of BCL6, thereby playing a role in the germinal centre B-cells terminal differentiation toward memory B-cells and plasma cells. The SCF(FBXO11) complex also mediates ubiquitination and degradation of DTL, an important step for the regulation of TGF-beta signalling, cell migration and the timing of the cell-cycle progression and exit. The SCF(FBXO11) complex also catalyses ubiquitination and degradation of GSK3B-phosphorylated SNAI1. Binds to and neddylates phosphorylated p53/TP53, inhibiting its transcriptional activity. Plays a role in the regulatiom of erythropoiesis but not myelopoiesis or megakaryopoiesis. Location: Nucleus; Chromosome (UniProt). Locus 2p16.3 (HGNC).
- Colorectal cancer: Open Targets association 0.79 with colorectal cancer (MONDO_0005575)
- Endometrial cancer: Open Targets association 0.74 with endometrial cancer (MONDO_0011962)
- Ovarian cancer: Open Targets association 0.72 with ovarian cancer (MONDO_0008170)
- Breast cancer: Open Targets association 0.69 with breast cancer (MONDO_0007254)
- Gastric & gastro-oesophageal junction cancer: Open Targets association 0.65 with gastric cancer (MONDO_0001056)
- Non-Hodgkin lymphoma: Open Targets association 0.62 with non-Hodgkin lymphoma (MONDO_0018908); IntOGen driver in 3 cohorts (MLYM, NHL)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 4 cohorts; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"FBXO11" OR ABSTRACT:"FBXO11" OR TITLE:"F-box protein 11" OR ABSTRACT:"F-box protein 11" OR TITLE:"F-box only protein 11" OR ABSTRACT:"F-box only protein 11" OR TITLE:"FBX11" OR ABSTRACT:"FBX11" OR TITLE:"UBR6" OR ABSTRACT:"UBR6") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FBXO11, not a curated reading list.